The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Baselga, 2012, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, 366, 520, 10.1056/NEJMoa1109653 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 Malumbres, 2009, Cell cycle, CDKs and cancer: a changing paradigm, Nat Rev Cancer, 9, 153, 10.1038/nrc2602 Stone, 2012, Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics, Crit Rev Oncog, 17, 175, 10.1615/CritRevOncog.v17.i2.40 Fry, 2004, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts, Mol Cancer Ther, 3, 1427, 10.1158/1535-7163.1427.3.11 Choi, 2014, Signaling through cyclin D-dependent kinases, Oncogene, 33, 1890, 10.1038/onc.2013.137 Finn, 2009, PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro, Breast Cancer Res, 11, R77, 10.1186/bcr2419 Finn, 2009, Cancer Res, 69 Mouridsen, 2003, Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group, J Clin Oncol, 21, 2101, 10.1200/JCO.2003.04.194 Grambsch, 1994, Proportional hazards tests and diagnostics based on weighted residuals, Biometrika, 81, 515, 10.1093/biomet/81.3.515 Chlebowski, 2013, Changing concepts of hormone receptor-positive advanced breast cancer therapy, Clin Breast Cancer, 13, 159, 10.1016/j.clbc.2012.11.002 Johnston, 2009, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer, J Clin Oncol, 27, 5538, 10.1200/JCO.2009.23.3734 Martin, 2012, Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer—first efficacy results from the LEA study, Cancer Res, 72, 10.1158/0008-5472.SABCS12-S1-7 Robertson, 2013, Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial, Lancet Oncol, 14, 228, 10.1016/S1470-2045(13)70026-3 Piccart, 2014, Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2, Eur J Cancer, 50, S1, 10.1016/S0959-8049(14)00221-4 Dean, 2012, Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors, Cell Cycle, 11, 2756, 10.4161/cc.21195 Miller, 2011, ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer, Cancer Discov, 1, 338, 10.1158/2159-8290.CD-11-0101 DeMichele A, Clark AS, Heitjan D, et al. A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer. 2013 ASCO Annual Meeting; Chicago, IL, USA; May 31–June 4, 2013. Abstr 519. Roberts, 2012, Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy, J Natl Cancer Inst, 104, 476, 10.1093/jnci/djs002